Latest Announcements

Ksolves India Limited has received a new order worth USD 0.5 million from Demerara Bank Limited to implement an Agentic AI solution.

Dilip Buildcon Limited has been declared as L-1 bidder for a Rs. 688.23 Crore order from National Highways Authority of India for the construction of a 4-lane elevated corridor in Solapur City, Maharashtra. The project will be executed on a Hybrid Annuity basis over 24 months with an operation period of 15 years.

Dilip Buildcon Ltd has been declared as L-1 bidder for a Rs. 688.23 Crores order for constructing a 4-lane elevated corridor in Solapur City, Maharashtra. The project will be executed on a Hybrid Annuity Mode (HAM) basis and will take 24 months to complete.

Ksolves India Ltd has received a new order worth USD 0.5 million from Demerara Bank Limited to implement an Agentic AI solution as a key strategic initiative.

Elitecon International Ltd has entered into a Product Supply Framework Agreement with World Class 77, South Africa, for potential export supplies of cut blended tobacco, homogenised tobacco, cigarettes, and fast-moving consumer goods, with an indicative programme ceiling of up to USD 60 million.

Dilip Buildcon Limited has been declared as L-1 bidder by REC Power Development and Consultancy Limited for the 'Development and Operation of Intra State Transmission System' project. The project involves the establishment of a 400 KV AIS Yavatmal (Babhulgaon) transmission system on a Build, Own, Operate and Transfer (BOOT) basis under Tariff Based Competitive Bidding (TBCB) route.

Dilip Buildcon Ltd has been declared as L-1 bidder by REC Power Development and Consultancy Limited for a 400 KV AIS Yavatmal (Babhulgaon) transmission project.

Lupin Limited has received tentative approval from the US FDA for its New Drug Application for Apixaban Oral Suspension 1.25mg/mL via the 505(b)(2) pathway.

Lupin Ltd has received tentative approval from the U.S. FDA for its New Drug Application for Apixaban Oral Suspension 1.25mg/mL via the 505(b)(2) pathway. The product will be manufactured at Lupin's Somerset, New Jersey facility, leveraging the company's U.S.-based manufacturing expertise to support high-quality standards and supply reliability.

Radico Khaitan Ltd has announced that its Indian luxury whisky brands, Rampur and Sangam, will be available across four major UK airports, marking a significant milestone in the company's global expansion strategy.

Radico Khaitan Limited has announced that its Indian luxury whisky brands, Rampur and Sangam, are now available at four major UK airports, marking a significant milestone in the company's global expansion strategy.

Morepen Laboratories Limited has submitted its first Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration for Sitagliptin Tablets USP in three strengths, marking a milestone in its integrated CDMO capabilities.

Morepen Laboratories Ltd has submitted its first U.S. ANDA for Sitagliptin Tablets USP in three strengths, strengthening its integrated CDMO capabilities and expanding its API-to-finished dosage development offering.

Kalpataru Projects International Limited (KPIL) has received a Letter of Award (LoA) for the Engineering, Procurement and Construction (EPC) of a gas pipeline project in the United Arab Emirates, valued over ₹4,000 crore.

Kalpataru Projects International Ltd has received a Letter of Award (LoA) for the Engineering, Procurement and Construction (EPC) of a gas pipeline project in the United Arab Emirates, with an estimated order value over ₹4,000 crore.

Indian Energy Exchange Ltd's wholly-owned subsidiary, Indian Coal Exchange Ltd, has applied for a licence with the Coal Controller Organisation (CCO) to operate as a coal exchange.

Lord's Mark Industries Ltd has secured registration with the Medicines & Healthcare products Regulatory Agency (MHRA), London, UK, for its AI-powered dialysis system, marking a major step towards taking its technology to the UK and UK-allied markets.

Sun Pharmaceutical Industries Limited has entered into a licensing agreement with LIB Therapeutics Inc. for the commercialization and manufacturing of lerodalcibep, a PCSK9 inhibitor, in territories outside the United States and China. The agreement grants Sun Pharma exclusive rights to the drug, which has received EU approval and is approved in the US under a different brand name.

Sun Pharmaceutical Industries Ltd has announced a global licensing agreement with LIB Therapeutics for the commercialization and manufacturing of lerodalcibep, a PCSK9 inhibitor, excluding the US and China. The agreement strengthens Sun Pharma's Innovative Medicines portfolio and provides access to a $3.7 billion PCSK9 market.

Man Infraconstruction Limited has partnered with Godrej Properties Group for the development of its sea-facing residential project at Marine Lines, South Mumbai, unlocking ₹6,000+ crores revenue potential and recouping ₹300+ crores investment.